Axa
NVAX icon

Axa’s Novavax NVAX Stock Holding History

Axa’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24,220
Closed -$3.46M – 1225
2021
Q4 		$3.46M Sell
24,220
-12,607
-34% -$2.17M 0.01% 754
2021
Q3 		$7.63M Buy
36,827
+1,356
+4% +$299K 0.02% 577
2021
Q2 		$7.53M Sell
35,471
-32,753
-48% -$6M 0.02% 591
2021
Q1 		$12.4M Buy
+68,224
New +$13.6M 0.04% 465
2020
Q2 		– Sell
-34,000
Closed -$462K – 1277
2020
Q1 		$462K Buy
+34,000
New +$288K ﹤0.01% 981
2016
Q3 		– Sell
-16,329
Closed -$2.37M – 1300
2016
Q2 		$2.37M Sell
16,329
-678
-4% -$77.7K 0.01% 711
2016
Q1 		$1.75M Sell
17,007
-920
-5% -$98.7K 0.01% 775
2015
Q4 		$3.01M Sell
17,927
-8,178
-31% -$1.26M 0.01% 695
2015
Q3 		$3.69M Buy
26,105
+8,087
+45% +$1.81M 0.02% 643
2015
Q2 		$4.01M Hold
18,018
– – 0.02% 637
2015
Q1 		$2.98M Buy
+18,018
New +$2.93M 0.01% 713

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Axa's NVAX Position: Q1 2022 in Review

Axa sold out of Novavax (NVAX) in Q1 2022, closing a stake of 24,220 shares — an estimated $3.46M sold.

Axa first reported a position in NVAX in Q1 2015 and held it in 11 quarters. The position peaked at $12.4M in Q1 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

  • Axa reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
  • Axa sold 24,220 Novavax shares in Q1 2022, an estimated $3.46M.
  • Axa first reported a position in Novavax in Q1 2015 and held it in 11 quarters.
  • Axa's Novavax position peaked at $12.4M in Q1 2021.
  • 381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on Axa's 13F filing for Q1 2022, filed 13 May 2022.